BridgeBio.
company in Palo Alto, United States
- Reports this week
- 0
- Active events
- 1
- Connections
- 82
What's happening
Earlier this month
One to three months ago
-
A BridgeBio executive spoke at congress in San Diego on October 7, 2026.Some support1 report
-
BridgeBio plans to submit MAA and NDA for infigratinib review to the FDA.Some support5 reports
-
BridgeBio and Novo Nordisk have both made filings under the KXCO Ontology.Some support1 report
-
BridgeBio CEO Kumar met with the Administration at the White House regarding expanding access to medicines via Medicare Part D.Some support1 report
-
Manufacturers committed to a $19.6B US manufacturing investment and contributing APIs to national reserves.Some support2 reports
-
BridgeBio presented data at the annual ESC Congress in 2026, with Marianna Fontana affiliated with UCL.Some support1 report
-
BridgeBio is conducting the ASCEND-ATTR study.Some support1 report
-
Alnylam and BridgeBio received label expansion approvals in the EU, while Pfizer's therapies compete in the ATTR-CM market.Well supported7 reports
-
BridgeBio submitted three late-stage pipeline drugs for review by the FDA.Some support2 reports1 development inside
-
BridgeBio was identified as a momentum stock by TipRanks and is seeking FDA approval for rare disease medications.Some support1 report2 developments inside
-
BridgeBio announced it filed a registration statement with the Securities and Exchange Commission (SEC), with William Blair & Company serving as joint book-running manager.Some support1 report
Gone quiet
No new reports in 90+ days-
FDA accepted the New Drug Application (NDA) for encaleret from BridgeBio.Some support3 reports
-
Citigroup and Truist Financial began research coverage and updated ratings for BridgeBio.Some support1 report
-
A trial failure involving BridgeBio and AstraZeneca has shifted market dynamics.Some support1 report
-
Sixth Street invested in BridgeBio equity on July 1, 2026.Some support1 report
-
BridgeBio is a company based in Palo Alto.Some support3 reports
-
BridgeBio will present data at ICCBH 2026 in Montreal.Some support3 reports
-
Matthew Wicklund is a professor and researcher at UT Health San Antonio, where he serves as a key figure.Speculative1 report
-
BridgeBio reaffirmed its Overweight rating, while encaleret testing for ADH1 and AI stocks benefit from tariffs.Speculative1 report
-
BridgeBio reported strong sales performance and benefits from Trump-era tariffs and onshoring trends, according to TD Cowen.Some support1 report
-
Wolfe Research initiated coverage of BridgeBio on June 21, 2025, with an 'Outperform' rating.Speculative1 report
-
BridgeBio sold part of its European royalty rights to Beyonttra.Speculative2 reports
-
BridgeBio reported that royalty revenue was generated from ex-U.S. net sales.Some support3 reports
-
Steve Cohen recommended BridgeBio as a top biotech stock on July 25, 2025.Some support3 reports
-
Zacks Earnings ESP compares estimates to actual results for BridgeBio on July 29, 2025.Some support1 report
-
BridgeBio, a company operating in the generic drugs sector, outperformed the market index on August 6, 2025.Some support1 report
-
BridgeBio is seeking Accelerated Approval from the FDA for a treatment that utilizes increased TTR stabilization, showing positive results for CVH events.Some support2 reports
-
BridgeBio hosted a healthcare investor conference in Boston on August 27, 2025.Some support1 report
-
Cantor Fitzgerald initiated coverage with a Buy rating on BridgeBio regarding its drug treatment for genetic diseases.Some support2 reports
-
BridgeBio presented ATTRibute-CM data at the ESC Congress 2025, demonstrating a statistically significant reduction in CVM risk.Some support2 reports
-
BridgeBio followed on LinkedIn and Twitter on September 2, 2025, while the ASBMR Annual Meeting was taking place in Seattle.Some support2 reports
No events began in the chosen period. Widen it, or reset.
What's reaching BridgeBio
Events traced to BridgeBio, step by step, newest firstAround BridgeBio this week
News at the entities that move BridgeBio most-
Donald Trump StructuralNPR investigated a detention plan implemented by the Trump administration, involving DHS policy officials.Moves BridgeBio
-
FDA StructuralThe FDA approved Miplyffa for the treatment of Niemann-Pick disease.Moves BridgeBio
-
BAYER StructuralDr. Andrea Maier-Richter was appointed Head of Coatings & Adhesives at Bayer AG, succeeding Thomas Römer.Moves BridgeBio
-
SEC StructuralDirector Arne Wilhelmsen sold shares of Royal Caribbean Cruises Ltd. and disclosed the transaction to the SEC.Moves BridgeBio
-
Fred Hassan StructuralFred Hassan was appointed non-executive chair of Recursion and holds board roles at Amgen, BridgeBio, and Prometheus.Moves BridgeBio
-
Barclays OperationalBarclays is expanding its operations in India, with Pramod Kumar appointed as CEO of the regional branch.Moves BridgeBio
Connections
The 39 strongest of 82, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
BAYER Structural
Bayer's commercialization drives BridgeBio's revenue, indicating a structural dependency.
-
Donald Trump Structural
BridgeBio's business operations are subject to specific policy benefits, agreements, and regulatory actions influenced by Donald Trump.
-
FDA Structural
BridgeBio's drug development and market viability are structurally dependent on FDA regulatory review and approval decisions.
-
SEC Structural
BridgeBio operates under the formal regulatory oversight of the SEC, requiring timely disclosure of corporate actions and filings.
-
Alnylam Pharmaceuticals Operational
BridgeBio and Alnylam Pharmaceuticals are active competitors vying for market share in the ATTR-CM therapeutic area.
-
Montreal Shared context
BridgeBio is scheduled to present company data at the ICCBH 2026 conference held in Montreal.
-
Kaiqi Sun Structural
Kaiqi Sun holds a leadership position overseeing company operations at BridgeBio.
-
Fred Hassan Structural
Fred Hassan held board roles at BridgeBio, establishing a formal governance relationship.
Show all 39 connections
-
Kumar Structural
Kumar serves as the Co-Founder and CEO of BridgeBio.
-
Sixth Street Transactional
Sixth Street made an equity investment in BridgeBio.
-
ASCEND Structural
BridgeBio is utilizing ASCEND's technology as part of the ASCEND-ATTR clinical study.
-
Nvidia Operational
The two companies compete in the market, with BridgeBio being significantly smaller than Nvidia.
-
AstraZeneca Operational
The relationship is characterized by active competition in the market, where the failure of clinical trials impacts market dynamics.
-
Medicare Operational
BridgeBio accesses the market through the established rules and structure of the Medicare Part D program.
-
Securities and Exchange Commission Structural
BridgeBio is subject to formal regulation by the Securities and Exchange Commission, evidenced by filing a registration statement.
-
Astellas Pharma Operational
Both companies participate in the national reserve system by contributing Active Pharmaceutical Ingredients (APIs).
-
James Li Structural
James Li holds an operational leadership role for BridgeBio in China.
-
Europe Operational
BridgeBio generates revenue and markets drugs in Europe through royalty rights and net sales.
-
TD Cowen Mentioned together
TD Cowen, an analyst firm, provides market coverage and target price recommendations for BridgeBio.
-
American Society for Bone and Mineral Research Operational
BridgeBio presented Phase 3 trial data at the American Society for Bone and Mineral Research meeting.
-
Pfizer Operational
BridgeBio and Pfizer are actively competing in the pharmaceutical market with their respective medicines.
-
Kumar Structural
Kumar founded and led BridgeBio.
-
Barclays Operational
Barclays issued an overweight rating and price target for BridgeBio.
-
White House Transactional
BridgeBio's CEO met with the White House Administration in 2018.
-
MarketBeat Mentioned together
MarketBeat serves as a data aggregator, collecting and presenting analyst ratings and market information specific to BridgeBio.
-
Reuters Mentioned together
Reuters, a major news agency, reported on BridgeBio's company activities and market participation.
-
European Society of Cardiology Shared context
BridgeBio presents scientific data at the European Society of Cardiology congress.
-
Twitter Mentioned together
BridgeBio utilizes Twitter as a communication platform for company and investor updates.
-
LinkedIn Operational
BridgeBio utilizes LinkedIn as a platform for corporate and investor communication.
-
Citigroup Mentioned together
Citigroup began providing research coverage on BridgeBio.
-
Truist Financial Mentioned together
Truist Financial provided market coverage of BridgeBio by raising target prices and issuing buy ratings.
-
William Blair & Company Transactional
William Blair & Company is engaged to provide joint book-running management services for BridgeBio's market activities.
-
Ravi Savarirayan Mentioned together
Savarirayan is the global lead investigator for the PROPEL 3 project.
-
Maa Mentioned together
The relationship is not supported by the current evidence, which only describes a corporate filing.
-
San Diego Shared context
BridgeBio executives have engaged in activities, such as speaking at congress, within the geographical context of San Diego.
-
Novo Nordisk Mentioned together
Both companies are categorized under the KXCO Ontology.
-
Palo Alto Shared context
BridgeBio is a company located in Palo Alto.
-
Indiana University Bloomington Mentioned together
A connection exists between BridgeBio and Indiana University Bloomington via a shared affiliated individual.
-
Ohio State University Mentioned together
The entities are co-mentioned in an article discussing an investigator's role.
History
Events by the month they beganOctober 2026
2 eventsSeptember 2026
1 eventAugust 2026
7 events- BridgeBio announced on August 14, 2026, that it has submitted New Drug Applications (NDAs) to the U.S. Food and Drug Administration (FDA).
- BridgeBio CEO Kumar met with the Administration at the White House regarding expanding access to medicines via Medicare Part D.
- Manufacturers committed to a $19.6B US manufacturing investment and contributing APIs to national reserves.
- BridgeBio presented data at the annual ESC Congress in 2026, with Marianna Fontana affiliated with UCL.
- BridgeBio is conducting the ASCEND-ATTR study.
- BridgeBio submitted three late-stage pipeline drugs for review by the FDA.
- BridgeBio announced it filed a registration statement with the Securities and Exchange Commission (SEC), with William Blair & Company serving as joint book-running manager.
Show 2 earlier months
July 2026
4 events- FDA accepted the New Drug Application (NDA) for encaleret from BridgeBio.
- Citigroup and Truist Financial began research coverage and updated ratings for BridgeBio.
- A trial failure involving BridgeBio and AstraZeneca has shifted market dynamics.
- Sixth Street invested in BridgeBio equity on July 1, 2026.
June 2026
19 events- BridgeBio plans to submit MAA and NDA for infigratinib review to the FDA.
- Alnylam and BridgeBio received label expansion approvals in the EU, while Pfizer's therapies compete in the ATTR-CM market.
- BridgeBio was identified as a momentum stock by TipRanks and is seeking FDA approval for rare disease medications.
- BridgeBio is a company based in Palo Alto.
- BridgeBio will present data at ICCBH 2026 in Montreal.
- Matthew Wicklund is a professor and researcher at UT Health San Antonio, where he serves as a key figure.
- BridgeBio reaffirmed its Overweight rating, while encaleret testing for ADH1 and AI stocks benefit from tariffs.
- BridgeBio reported strong sales performance and benefits from Trump-era tariffs and onshoring trends, according to TD Cowen.
- Wolfe Research initiated coverage of BridgeBio on June 21, 2025, with an 'Outperform' rating.
- BridgeBio sold part of its European royalty rights to Beyonttra.
- BridgeBio reported that royalty revenue was generated from ex-U.S. net sales.
- Steve Cohen recommended BridgeBio as a top biotech stock on July 25, 2025.
- Zacks Earnings ESP compares estimates to actual results for BridgeBio on July 29, 2025.
- BridgeBio, a company operating in the generic drugs sector, outperformed the market index on August 6, 2025.
- BridgeBio is seeking Accelerated Approval from the FDA for a treatment that utilizes increased TTR stabilization, showing positive results for CVH events.
- BridgeBio hosted a healthcare investor conference in Boston on August 27, 2025.
- Cantor Fitzgerald initiated coverage with a Buy rating on BridgeBio regarding its drug treatment for genetic diseases.
- BridgeBio presented ATTRibute-CM data at the ESC Congress 2025, demonstrating a statistically significant reduction in CVM risk.
- BridgeBio followed on LinkedIn and Twitter on September 2, 2025, while the ASBMR Annual Meeting was taking place in Seattle.